Platelet-Related Prognostic Genes and Risk Model for Acute Myeloid Leukemia

Four platelet-related prognostic genes (SH2B3, PTPN11, NHLRC2, CD9) were identified from transcriptomic and clinical data of Acute Myeloid Leukemia patients. A risk model built using these genes was validated across training and test cohorts, with analyses covering immune microenvironment composition and drug sensitivity predictions. Experimental validation via RT-qPCR confirmed the bioinformatics findings.

Use Cases

• Building a prognostic risk score for AML patients based on expression of SH2B3, PTPN11, NHLRC2, and CD9.
• Analyzing associations between platelet-related genes and immune cell infiltration (e.g., CD8+ T cells, plasma cells).
• Predicting drug sensitivity for therapies like bexarotene, dasatinib, ATRA, and axitinib based on patient risk group.
• Conducting functional enrichment analysis on gene sets involved in immune-related pathways such as antimicrobial humoral response.

Strengths

• Model validation was performed across multiple cohorts, including training and validation groups.
• Findings are supported by both bioinformatics analysis and experimental RT-qPCR validation on clinical samples.
• Analysis integrates multiple data types: gene expression, clinical outcomes, immune microenvironment, and drug sensitivity.

Limitations

• Specific column names and row counts for the underlying data are not provided, limiting reproducibility.
• The original data sources (GEO datasets) are referenced, but the exact patient cohorts and preprocessing steps are not detailed.

Provenance

Source

Gene Expression Omnibus (GEO) datasets GSE114868, GSE71014, GSE12417.

Collection Method

Bioinformatics analysis of transcriptomic and clinical data, followed by experimental RT-qPCR validation.

Time Range

null

Freshness

Last updated 2026-03-21.

Geography

null